CD169, also known as Siglec-1 and Sialoadhesin (Sn), is a type I lectin containing 17 immunoglobulin (Ig) domains (one variable domain and 16 constant domains). CD169 binds to sialic acids, which can be found on PSGL-1, CD43, CD206, and CD227. By its affinity to α2, 3-linked sialic acid, it is involved in macrophage binding to different cell types such as granulocytes, monocytes, NK, B, and T cells. CD169 was initially identified as a sialic acid-dependent sheep erythrocyte receptor (SER) on resident bone marrow cells of mice. It has been identified as highly expressed on resident bone marrow macrophages which plays an important role in retention of stem cells in mesenchymal stem cell niche. It is also found on some specific subsets of tissue macrophages in spleen, lymph nodes, bone marrow, liver, colon, lungs, and cancer cells. Evidence suggest that CD169-positive macrophages serve as lymph node-resident APCs to dominate early activation of tumor antigen-specific CD8⁺ T cells and invariant NK cell.

PRODUCT DETAILS

Clone: 3D6.112

Antibody Type: Monoclonal

Reactivity: Mouse

Format: BV605

Host: Rat

Isotype: IgG2a, κ

Applications: FC - Quality tested

Regulatory Status: RUO

Data Sheets: TDS | SDS

Note to Purchaser: This product is manufactured and supplied by BioLegend, Inc. under an agreement between BioLegend, Inc. and Cytek Biosciences, Inc. Information related to this product is provided by BioLegend, Inc.